Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study

Background The purpose of this study was to characterize the pharmacokinetics of 2 homologues of phosphatidylethanol (PEth) and their combined total in uncoagulated, whole blood samples taken from participants in a human clinical laboratory study after consumption of low doses of ethanol (EtOH). Met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alcoholism, clinical and experimental research clinical and experimental research, 2016-06, Vol.40 (6), p.1228-1234
Hauptverfasser: Javors, Martin A., Hill-Kapturczak, Nathalie, Roache, John D., Karns-Wright, Tara E., Dougherty, Donald M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1234
container_issue 6
container_start_page 1228
container_title Alcoholism, clinical and experimental research
container_volume 40
creator Javors, Martin A.
Hill-Kapturczak, Nathalie
Roache, John D.
Karns-Wright, Tara E.
Dougherty, Donald M.
description Background The purpose of this study was to characterize the pharmacokinetics of 2 homologues of phosphatidylethanol (PEth) and their combined total in uncoagulated, whole blood samples taken from participants in a human clinical laboratory study after consumption of low doses of ethanol (EtOH). Methods As part of a larger study, 14 male and 13 female participants received either 0.25 or 0.50 g/kg oral doses of EtOH during a 15‐minute period. Blood samples were collected before and throughout 6 hours after each EtOH dose on the day of consumption and then every 3 days during the next 14 days. PEth 16:0/18:1 and PEth 16:0/18:2 levels were quantified in blood samples by HPLC/MS/MS and reported separately or as their combined total (combined PEth). Breath alcohol concentrations (BrACs) were measured concurrently with each blood collection. Transdermal alcohol concentrations were measured every 30 minutes during the entire 22‐day study to confirm the absence of drinking during a 7‐day period before and the 14‐day period after EtOH consumption. Results (i) Single doses of 0.25 and 0.50 g EtOH/kg produced proportional increases in BrAC and combined PEth levels of all participants; (ii) the areas under the curve (AUCs) for each participant's BrAC levels during the 6‐hour period after EtOH administration were correlated with AUCs of cPEth (calculated as the AUC of the increase above baseline for combined PEth); (iii) the mean half‐life of combined PEth, determined during the 14‐day period after EtOH consumption, was 4.6 ± 3.5 (SD) days (range: 1.0 to 13.1 days). Conclusions Combined PEth is a sensitive biomarker for the identification of relatively low levels of EtOH consumption. The measurement of these 2 homologues may provide additional sensitivity to identify low levels of drinking. The purpose of this study was to characterize the pharmacokinetics of PEth 16:0/18:1 and 16:0/18:2 in blood of 27 participants in a human laboratory study. Blood samples were collected immediately after consumption of low (0.25 and 0.50 g/kg) doses of ethanol and then every 3 days for 2 weeks during abstinence. Our results indicate that ethanol produced increased PEth levels in all participants and PEth levels correlated with absorption of ethanol. Also, the measurement of these 2 PEth homologues may provide additional information to estimate the time from last, previous drinking.
doi_str_mv 10.1111/acer.13062
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808716809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1793567065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4642-3434cf418a8cc35ba563e02450095de90696ecbb68a90986e87745bc1f308f093</originalsourceid><addsrcrecordid>eNqN0c1u1DAQB_AIgWgpXHgAZIkLQko7juOP9LaNSgtaQVVAK3GxHMdR3DrxYieC5X14T7zddg8cEL5YHv1mRtY_y15iOMbpnChtwjEmwIpH2SGmBHIoOH-cHQIuac4AxEH2LMYbACgFY0-zg4InTgt-mP2uexWUnkywv9Rk_Yh8h6beoKtUH5T2t3Y0k9VxW7_qfVz3ibUbZ6Zejd4hzE7hBItTjNTY7l8FsiO6nAc1olXvnUFnzvsWLbq0CC2c9qmIaj_GeVjfbU1codrZ0Wrl0FI1PqjJhw36PM3t5nn2pFMumhf391H29d35l_oyX366eF8vlrkuWVnkpCSl7koslNCa0EZRRgwUJQWoaGsqYBUzummYUBVUghnBeUkbjTsCooOKHGVvdnPXwX-fTZzkYKM2zqnR-DlKLEBwzMT_UF4Ryjgwmujrv-iNn8OYPrJVBWO8qEhSb3dKBx9jMJ1cBzuosJEY5DZnuc1Z3uWc8Kv7kXMzmHZPH4JNAO_AD-vM5h-j5KI-v34Ymu96bJzMz32PCreSccKpXH28kB_Y6tv1GVRSkD-vtL8U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792667293</pqid></control><display><type>article</type><title>Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Journals@Ovid Complete</source><creator>Javors, Martin A. ; Hill-Kapturczak, Nathalie ; Roache, John D. ; Karns-Wright, Tara E. ; Dougherty, Donald M.</creator><creatorcontrib>Javors, Martin A. ; Hill-Kapturczak, Nathalie ; Roache, John D. ; Karns-Wright, Tara E. ; Dougherty, Donald M.</creatorcontrib><description>Background The purpose of this study was to characterize the pharmacokinetics of 2 homologues of phosphatidylethanol (PEth) and their combined total in uncoagulated, whole blood samples taken from participants in a human clinical laboratory study after consumption of low doses of ethanol (EtOH). Methods As part of a larger study, 14 male and 13 female participants received either 0.25 or 0.50 g/kg oral doses of EtOH during a 15‐minute period. Blood samples were collected before and throughout 6 hours after each EtOH dose on the day of consumption and then every 3 days during the next 14 days. PEth 16:0/18:1 and PEth 16:0/18:2 levels were quantified in blood samples by HPLC/MS/MS and reported separately or as their combined total (combined PEth). Breath alcohol concentrations (BrACs) were measured concurrently with each blood collection. Transdermal alcohol concentrations were measured every 30 minutes during the entire 22‐day study to confirm the absence of drinking during a 7‐day period before and the 14‐day period after EtOH consumption. Results (i) Single doses of 0.25 and 0.50 g EtOH/kg produced proportional increases in BrAC and combined PEth levels of all participants; (ii) the areas under the curve (AUCs) for each participant's BrAC levels during the 6‐hour period after EtOH administration were correlated with AUCs of cPEth (calculated as the AUC of the increase above baseline for combined PEth); (iii) the mean half‐life of combined PEth, determined during the 14‐day period after EtOH consumption, was 4.6 ± 3.5 (SD) days (range: 1.0 to 13.1 days). Conclusions Combined PEth is a sensitive biomarker for the identification of relatively low levels of EtOH consumption. The measurement of these 2 homologues may provide additional sensitivity to identify low levels of drinking. The purpose of this study was to characterize the pharmacokinetics of PEth 16:0/18:1 and 16:0/18:2 in blood of 27 participants in a human laboratory study. Blood samples were collected immediately after consumption of low (0.25 and 0.50 g/kg) doses of ethanol and then every 3 days for 2 weeks during abstinence. Our results indicate that ethanol produced increased PEth levels in all participants and PEth levels correlated with absorption of ethanol. Also, the measurement of these 2 PEth homologues may provide additional information to estimate the time from last, previous drinking.</description><identifier>ISSN: 0145-6008</identifier><identifier>EISSN: 1530-0277</identifier><identifier>DOI: 10.1111/acer.13062</identifier><identifier>PMID: 27130527</identifier><identifier>CODEN: ACRSDM</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Alcohol Drinking - blood ; Biomarkers - blood ; Blood ; Breath Tests ; Dose-Response Relationship, Drug ; Ethanol ; Ethanol - blood ; Ethanol - pharmacokinetics ; Female ; Glycerophospholipids - blood ; Glycerophospholipids - pharmacokinetics ; HPLC/MS/MS ; Humans ; Male ; Middle Aged ; Pharmacokinetics ; Phosphatidylethanol ; Young Adult</subject><ispartof>Alcoholism, clinical and experimental research, 2016-06, Vol.40 (6), p.1228-1234</ispartof><rights>Copyright © 2016 by the Research Society on Alcoholism</rights><rights>Copyright © 2016 by the Research Society on Alcoholism.</rights><rights>2016 Research Society on Alcoholism</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4642-3434cf418a8cc35ba563e02450095de90696ecbb68a90986e87745bc1f308f093</citedby><cites>FETCH-LOGICAL-c4642-3434cf418a8cc35ba563e02450095de90696ecbb68a90986e87745bc1f308f093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Facer.13062$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Facer.13062$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27130527$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javors, Martin A.</creatorcontrib><creatorcontrib>Hill-Kapturczak, Nathalie</creatorcontrib><creatorcontrib>Roache, John D.</creatorcontrib><creatorcontrib>Karns-Wright, Tara E.</creatorcontrib><creatorcontrib>Dougherty, Donald M.</creatorcontrib><title>Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study</title><title>Alcoholism, clinical and experimental research</title><addtitle>Alcohol Clin Exp Res</addtitle><description>Background The purpose of this study was to characterize the pharmacokinetics of 2 homologues of phosphatidylethanol (PEth) and their combined total in uncoagulated, whole blood samples taken from participants in a human clinical laboratory study after consumption of low doses of ethanol (EtOH). Methods As part of a larger study, 14 male and 13 female participants received either 0.25 or 0.50 g/kg oral doses of EtOH during a 15‐minute period. Blood samples were collected before and throughout 6 hours after each EtOH dose on the day of consumption and then every 3 days during the next 14 days. PEth 16:0/18:1 and PEth 16:0/18:2 levels were quantified in blood samples by HPLC/MS/MS and reported separately or as their combined total (combined PEth). Breath alcohol concentrations (BrACs) were measured concurrently with each blood collection. Transdermal alcohol concentrations were measured every 30 minutes during the entire 22‐day study to confirm the absence of drinking during a 7‐day period before and the 14‐day period after EtOH consumption. Results (i) Single doses of 0.25 and 0.50 g EtOH/kg produced proportional increases in BrAC and combined PEth levels of all participants; (ii) the areas under the curve (AUCs) for each participant's BrAC levels during the 6‐hour period after EtOH administration were correlated with AUCs of cPEth (calculated as the AUC of the increase above baseline for combined PEth); (iii) the mean half‐life of combined PEth, determined during the 14‐day period after EtOH consumption, was 4.6 ± 3.5 (SD) days (range: 1.0 to 13.1 days). Conclusions Combined PEth is a sensitive biomarker for the identification of relatively low levels of EtOH consumption. The measurement of these 2 homologues may provide additional sensitivity to identify low levels of drinking. The purpose of this study was to characterize the pharmacokinetics of PEth 16:0/18:1 and 16:0/18:2 in blood of 27 participants in a human laboratory study. Blood samples were collected immediately after consumption of low (0.25 and 0.50 g/kg) doses of ethanol and then every 3 days for 2 weeks during abstinence. Our results indicate that ethanol produced increased PEth levels in all participants and PEth levels correlated with absorption of ethanol. Also, the measurement of these 2 PEth homologues may provide additional information to estimate the time from last, previous drinking.</description><subject>Adult</subject><subject>Alcohol Drinking - blood</subject><subject>Biomarkers - blood</subject><subject>Blood</subject><subject>Breath Tests</subject><subject>Dose-Response Relationship, Drug</subject><subject>Ethanol</subject><subject>Ethanol - blood</subject><subject>Ethanol - pharmacokinetics</subject><subject>Female</subject><subject>Glycerophospholipids - blood</subject><subject>Glycerophospholipids - pharmacokinetics</subject><subject>HPLC/MS/MS</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pharmacokinetics</subject><subject>Phosphatidylethanol</subject><subject>Young Adult</subject><issn>0145-6008</issn><issn>1530-0277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c1u1DAQB_AIgWgpXHgAZIkLQko7juOP9LaNSgtaQVVAK3GxHMdR3DrxYieC5X14T7zddg8cEL5YHv1mRtY_y15iOMbpnChtwjEmwIpH2SGmBHIoOH-cHQIuac4AxEH2LMYbACgFY0-zg4InTgt-mP2uexWUnkywv9Rk_Yh8h6beoKtUH5T2t3Y0k9VxW7_qfVz3ibUbZ6Zejd4hzE7hBItTjNTY7l8FsiO6nAc1olXvnUFnzvsWLbq0CC2c9qmIaj_GeVjfbU1codrZ0Wrl0FI1PqjJhw36PM3t5nn2pFMumhf391H29d35l_oyX366eF8vlrkuWVnkpCSl7koslNCa0EZRRgwUJQWoaGsqYBUzummYUBVUghnBeUkbjTsCooOKHGVvdnPXwX-fTZzkYKM2zqnR-DlKLEBwzMT_UF4Ryjgwmujrv-iNn8OYPrJVBWO8qEhSb3dKBx9jMJ1cBzuosJEY5DZnuc1Z3uWc8Kv7kXMzmHZPH4JNAO_AD-vM5h-j5KI-v34Ymu96bJzMz32PCreSccKpXH28kB_Y6tv1GVRSkD-vtL8U</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Javors, Martin A.</creator><creator>Hill-Kapturczak, Nathalie</creator><creator>Roache, John D.</creator><creator>Karns-Wright, Tara E.</creator><creator>Dougherty, Donald M.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K7.</scope><scope>K9.</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201606</creationdate><title>Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study</title><author>Javors, Martin A. ; Hill-Kapturczak, Nathalie ; Roache, John D. ; Karns-Wright, Tara E. ; Dougherty, Donald M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4642-3434cf418a8cc35ba563e02450095de90696ecbb68a90986e87745bc1f308f093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Alcohol Drinking - blood</topic><topic>Biomarkers - blood</topic><topic>Blood</topic><topic>Breath Tests</topic><topic>Dose-Response Relationship, Drug</topic><topic>Ethanol</topic><topic>Ethanol - blood</topic><topic>Ethanol - pharmacokinetics</topic><topic>Female</topic><topic>Glycerophospholipids - blood</topic><topic>Glycerophospholipids - pharmacokinetics</topic><topic>HPLC/MS/MS</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pharmacokinetics</topic><topic>Phosphatidylethanol</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javors, Martin A.</creatorcontrib><creatorcontrib>Hill-Kapturczak, Nathalie</creatorcontrib><creatorcontrib>Roache, John D.</creatorcontrib><creatorcontrib>Karns-Wright, Tara E.</creatorcontrib><creatorcontrib>Dougherty, Donald M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Alcoholism, clinical and experimental research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javors, Martin A.</au><au>Hill-Kapturczak, Nathalie</au><au>Roache, John D.</au><au>Karns-Wright, Tara E.</au><au>Dougherty, Donald M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study</atitle><jtitle>Alcoholism, clinical and experimental research</jtitle><addtitle>Alcohol Clin Exp Res</addtitle><date>2016-06</date><risdate>2016</risdate><volume>40</volume><issue>6</issue><spage>1228</spage><epage>1234</epage><pages>1228-1234</pages><issn>0145-6008</issn><eissn>1530-0277</eissn><coden>ACRSDM</coden><abstract>Background The purpose of this study was to characterize the pharmacokinetics of 2 homologues of phosphatidylethanol (PEth) and their combined total in uncoagulated, whole blood samples taken from participants in a human clinical laboratory study after consumption of low doses of ethanol (EtOH). Methods As part of a larger study, 14 male and 13 female participants received either 0.25 or 0.50 g/kg oral doses of EtOH during a 15‐minute period. Blood samples were collected before and throughout 6 hours after each EtOH dose on the day of consumption and then every 3 days during the next 14 days. PEth 16:0/18:1 and PEth 16:0/18:2 levels were quantified in blood samples by HPLC/MS/MS and reported separately or as their combined total (combined PEth). Breath alcohol concentrations (BrACs) were measured concurrently with each blood collection. Transdermal alcohol concentrations were measured every 30 minutes during the entire 22‐day study to confirm the absence of drinking during a 7‐day period before and the 14‐day period after EtOH consumption. Results (i) Single doses of 0.25 and 0.50 g EtOH/kg produced proportional increases in BrAC and combined PEth levels of all participants; (ii) the areas under the curve (AUCs) for each participant's BrAC levels during the 6‐hour period after EtOH administration were correlated with AUCs of cPEth (calculated as the AUC of the increase above baseline for combined PEth); (iii) the mean half‐life of combined PEth, determined during the 14‐day period after EtOH consumption, was 4.6 ± 3.5 (SD) days (range: 1.0 to 13.1 days). Conclusions Combined PEth is a sensitive biomarker for the identification of relatively low levels of EtOH consumption. The measurement of these 2 homologues may provide additional sensitivity to identify low levels of drinking. The purpose of this study was to characterize the pharmacokinetics of PEth 16:0/18:1 and 16:0/18:2 in blood of 27 participants in a human laboratory study. Blood samples were collected immediately after consumption of low (0.25 and 0.50 g/kg) doses of ethanol and then every 3 days for 2 weeks during abstinence. Our results indicate that ethanol produced increased PEth levels in all participants and PEth levels correlated with absorption of ethanol. Also, the measurement of these 2 PEth homologues may provide additional information to estimate the time from last, previous drinking.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27130527</pmid><doi>10.1111/acer.13062</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0145-6008
ispartof Alcoholism, clinical and experimental research, 2016-06, Vol.40 (6), p.1228-1234
issn 0145-6008
1530-0277
language eng
recordid cdi_proquest_miscellaneous_1808716809
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Journals@Ovid Complete
subjects Adult
Alcohol Drinking - blood
Biomarkers - blood
Blood
Breath Tests
Dose-Response Relationship, Drug
Ethanol
Ethanol - blood
Ethanol - pharmacokinetics
Female
Glycerophospholipids - blood
Glycerophospholipids - pharmacokinetics
HPLC/MS/MS
Humans
Male
Middle Aged
Pharmacokinetics
Phosphatidylethanol
Young Adult
title Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A48%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20Pharmacokinetics%20of%20Phosphatidylethanol%2016:0/18:1%20and%2016:0/18:2%20in%20Human%20Whole%20Blood%20After%20Alcohol%20Consumption%20in%20a%20Clinical%20Laboratory%20Study&rft.jtitle=Alcoholism,%20clinical%20and%20experimental%20research&rft.au=Javors,%20Martin%20A.&rft.date=2016-06&rft.volume=40&rft.issue=6&rft.spage=1228&rft.epage=1234&rft.pages=1228-1234&rft.issn=0145-6008&rft.eissn=1530-0277&rft.coden=ACRSDM&rft_id=info:doi/10.1111/acer.13062&rft_dat=%3Cproquest_cross%3E1793567065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1792667293&rft_id=info:pmid/27130527&rfr_iscdi=true